You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 3, 2024

~ Buy the VEREGEN (sinecatechins) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR VEREGEN

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for VEREGEN

Subscribe to access the full database, or Try a Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01082302 ↗	Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage	Completed	Charité Research Organisation GmbH	Phase 4	2010-01-01	This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.
NCT01082302 ↗	Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage	Completed	Charité Research Organization GmbH	Phase 4	2010-01-01	This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.
NCT01082302 ↗	Pharmacokinetic Study of Topically Applied Veregen 15% Compared With Oral Intake of Green Tea Beverage	Completed	MediGene	Phase 4	2010-01-01	This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for VEREGEN

Condition Name

Chart
Table

Condition Name for VEREGEN
Intervention	Trials
Genital Warts	1
Genito-Pelvic Pain/Penetration Disorder	1
Lamellar Ichthyosis	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for VEREGEN
Intervention	Trials
Warts	4
Condylomata Acuminata	3
Pelvic Pain	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for VEREGEN

Trials by Country

Map
Table

Trials by Country for VEREGEN
Location	Trials
United States	27
Germany	2
France	1
Guam	1
Netherlands	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for VEREGEN
Location	Trials
Texas	2
New York	2
South Carolina	1
Virginia	1
Washington	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for VEREGEN

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for VEREGEN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2/Phase 3	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for VEREGEN
Clinical Trial Phase	Trials
Completed	5
Recruiting	1
Terminated	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for VEREGEN

Sponsor Name

Chart
Table

Sponsor Name for VEREGEN
Sponsor	Trials
MediGene	2
Will-Pharma	1
Maastricht University Medical Center	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for VEREGEN
Sponsor	Trials
Other	8
Industry	5
NIH	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.